Performance assessment of novel chemiluminescence immunoassays for the detection of specific biomarkers for Alzheimer’s disease

Philipp Arendt, Katharina Römpler, Britta Brix, Stephanie Franco, Viola Borchardt‐Lohölter, Anette Schulz, Mandy Busse, Stefan Busse · 2025

Read Performance assessment of novel chemiluminescence immunoassays for the detection of specific biomarkers for Alzheimer’s disease by Philipp Arendt, Katharina Römpler, Britta Brix, Stephanie Franco, Viola Borchardt‐Lohölter, Anette Schulz, Mandy Busse, Stefan Busse (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11716885.txt.

Description

Philipp Arendt and co-authors compare, in a 2025 study, new lab tests for Alzheimer's disease against a well-established rival set. The tests measure amyloid and tau proteins in spinal fluid, the classic way labs support a diagnosis of the disease.

Both sets of tests were run on 110 spinal fluid samples from patients with no known diagnosis. The new tests come from EUROIMMUN, and the comparison set runs on a widely used machine from another maker. The team checked how closely the numbers agreed across the four markers. Close agreement would let more labs offer the tests with confidence that results mean the same thing from place to place.

Catalog record

CREATORPhilipp Arendt, Katharina Römpler, Britta Brix, Stephanie Franco, Viola Borchardt‐Lohölter, Anette Schulz, Mandy Busse, Stefan Busse
YEAR2025
COLLECTIONPAPERS
FORMATTXT
FILE SIZE2 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC11716885

Browse the full library · About the Tower of Babel